1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Severe Psoriasis-Pipeline Insights, 2017

Severe Psoriasis-Pipeline Insights, 2017

  • January 2017
  • -
  • Delve Insight


DelveInsight’s, “ Severe Psoriasis-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Severe Psoriasis. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Severe Psoriasis. DelveInsight’s Report also assesses the Severe Psoriasis therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Severe Psoriasis
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Severe Psoriasis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Severe Psoriasis and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Severe Psoriasis-Pipeline Insights, 2017
Illustrative

- Severe Psoriasis Overview
- Severe Psoriasis Pipeline Therapeutics
- Severe Psoriasis Therapeutics under Development by Companies
- Severe Psoriasis Filed and Phase III Products
- Comparative Analysis
- Severe Psoriasis Phase II Products
- Comparative Analysis
- Severe Psoriasis Phase I and IND Filed Products
- Comparative Analysis
- Severe Psoriasis Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Severe Psoriasis - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Severe Psoriasis - Discontinued Products
- Severe Psoriasis - Dormant Products
- Companies Involved in Therapeutics Development for Severe Psoriasis
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Severe Psoriasis, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Severe Psoriasis Assessment by Monotherapy Products
- Severe Psoriasis Assessment by Combination Products
- Severe Psoriasis Assessment by Route of Administration
- Severe Psoriasis Assessment by Stage and Route of Administration
- Severe Psoriasis Assessment by Molecule Type
- Severe Psoriasis Assessment by Stage and Molecule Type
- Severe Psoriasis Therapeutics - Discontinued Products
- Severe Psoriasis Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Severe Psoriasis, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Severe Psoriasis Assessment by Monotherapy Products
- Severe Psoriasis Assessment by Combination Products
- Severe Psoriasis Assessment by Route of Administration
- Severe Psoriasis Assessment by Stage and Route of Administration
- Severe Psoriasis Assessment by Molecule Type
- Severe Psoriasis Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Global Scleroderma Diagnostics and Therapeutics Market: Overview Scleroderma, a very rare autoimmune disorder of the skin, is a term coined from the Greek words “sklerosis,” which means hardness, and ...

Ankylosing spondylitis (AS)- Market Insights, Epidemiology and Market Forecast-2023

Ankylosing spondylitis (AS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Ankylosing spondylitis (AS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Diabetes Statistics in China

  • February 2017
    13 pages
  • Diabetes  

  • China  

View report >

Influenza Statistics in the US

  • February 2017
    9 pages
  • Influenza  

  • United States  

View report >

Autoimmune Disease Statistics in the US

  • February 2017
    9 pages
  • Autoimmune Dise...  

    Hospital  

  • United States  

View report >

Chromosome Industry

17 days ago

Related Market Segments :

Autoimmune Disease

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.